sulfinpyrazone has been researched along with Ventricular Fibrillation in 8 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the relative importance of arachidonic acid pathway products on vulnerability to ventricular fibrillation (VF), we examined the effects of synthesis inhibitors and a receptor blocker acting in the cyclooxygenase (C) and lipoxygenase (L) pathways on VF thresholds in a feline model of coronary occlusion." | 7.67 | Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. ( Cooper, DR; Kelliher, GJ; Kowey, PR, 1988) |
| "In patients treated with sulfinpyrazone, an apparent reduction in the incidence of sudden death and presumed ventricular fibrillation has been reported." | 7.66 | Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. ( Escobinas, AJ; Jorgensen, OB; Moschos, CB; Regan, TJ, 1981) |
| " A recent double-blind multicenter trial ("Anturane Reinfarction Trial") showed that the incidence of sudden cardiac death was reduced in Sulfinpyrazone-treated patients after acute myocardial infarction compared with the placebo group, although the rate of reinfarctions was not diminished." | 7.66 | [Effects of sulfinpyrazone on early ventricular fibrillation and 2d-phase arrhythmias in acute myocardial infarction (author's transl)]. ( Bender, F; Dorsel, T; Gülker, H; Heuer, H; Kristek, J; Pierchalla, P; Thale, J, 1980) |
| "To determine the relative importance of arachidonic acid pathway products on vulnerability to ventricular fibrillation (VF), we examined the effects of synthesis inhibitors and a receptor blocker acting in the cyclooxygenase (C) and lipoxygenase (L) pathways on VF thresholds in a feline model of coronary occlusion." | 3.67 | Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. ( Cooper, DR; Kelliher, GJ; Kowey, PR, 1988) |
| "In patients treated with sulfinpyrazone, an apparent reduction in the incidence of sudden death and presumed ventricular fibrillation has been reported." | 3.66 | Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. ( Escobinas, AJ; Jorgensen, OB; Moschos, CB; Regan, TJ, 1981) |
| " A recent double-blind multicenter trial ("Anturane Reinfarction Trial") showed that the incidence of sudden cardiac death was reduced in Sulfinpyrazone-treated patients after acute myocardial infarction compared with the placebo group, although the rate of reinfarctions was not diminished." | 3.66 | [Effects of sulfinpyrazone on early ventricular fibrillation and 2d-phase arrhythmias in acute myocardial infarction (author's transl)]. ( Bender, F; Dorsel, T; Gülker, H; Heuer, H; Kristek, J; Pierchalla, P; Thale, J, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boissel, JP | 1 |
| Leizorovicz, A | 1 |
| Faucomprez, C | 1 |
| Packham, MA | 1 |
| Mustard, JF | 1 |
| Raeder, EA | 1 |
| Verrier, RL | 1 |
| Lown, B | 1 |
| Russell, DC | 1 |
| Moschos, CB | 1 |
| Escobinas, AJ | 1 |
| Jorgensen, OB | 1 |
| Regan, TJ | 1 |
| Gülker, H | 1 |
| Bender, F | 1 |
| Thale, J | 1 |
| Heuer, H | 1 |
| Kristek, J | 1 |
| Dorsel, T | 1 |
| Pierchalla, P | 1 |
| Eller, BT | 1 |
| Lynch, JJ | 1 |
| Patterson, E | 1 |
| Lucchesi, BR | 1 |
| Cooper, DR | 1 |
| Kelliher, GJ | 1 |
| Kowey, PR | 1 |
2 reviews available for sulfinpyrazone and Ventricular Fibrillation
| Article | Year |
|---|---|
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
Pharmacology of platelet-affecting drugs.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Cyclic AMP; Dose-Response Re | 1980 |
1 trial available for sulfinpyrazone and Ventricular Fibrillation
| Article | Year |
|---|---|
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
6 other studies available for sulfinpyrazone and Ventricular Fibrillation
| Article | Year |
|---|---|
Effects of sulfinpyrazone on ventricular vulnerability in the normal and the ischemic heart.
Topics: Animals; Coronary Disease; Dogs; Female; Heart; Heart Conduction System; Lidocaine; Male; Myocardial | 1982 |
Haemodynamic effects of sulphinpyrazone in experimental myocardial ischaemia.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Dogs; Heart Rate; Hemodynamics; Sulfinpyrazone; V | 1981 |
Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia.
Topics: Acute Disease; Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Disease; Dogs; Electro | 1981 |
[Effects of sulfinpyrazone on early ventricular fibrillation and 2d-phase arrhythmias in acute myocardial infarction (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Myocardial Infarction; Sulfinpyrazone; Ventricular Fibrillation | 1980 |
Electrophysiologic and antiarrhythmic actions of sulphinpyrazone and its sulfide metabolite G25671.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Cyclooxygenase Inhibitors; Dogs; Electrophysiolog | 1987 |
Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents, Non | 1988 |